Product highlights
- The issuer’s Form 10-K signed February 23, 2026 explicitly identifies Ekso Nomad as a powered knee-ankle-foot orthosis (KAFO). It is a named device, not merely a fleet-software label or another spelling of Indego Personal.
- That report described limited-volume sale for one non-company-sponsored clinical study and conditionally targeted general commercialization for late 2026. Clinical-study supply and a future rollout expectation are distinct; general market delivery has not been verified as of November 2, 2026.
- Parker Human Motion Control acquisition on December 5, 2022 included Nomad-related intellectual property. An IP acquisition date is not a device first-release date, regulatory decision or guarantee that present hardware matches another Indego device.
- The selected issuer text does not establish an exact device mass, dimensions, battery endurance, speed, price or control interface. Broader market availability, current regulatory status, coverage and clinical outcomes require evidence beyond the dated rollout forecast.
Product sources
- Ekso Bionics — issuer 2025 Form 10-K signed February 23, 2026; dated products and conditional Nomad rollout · Manufacturer source · Checked 2026-11-02
Description
Ekso Nomad is the powered knee-ankle-foot orthosis named in the issuer’s 2025 Form 10-K signed February 23, 2026. That dated report described limited-volume sales for a single non-company-sponsored clinical study and conditionally expected general commercialization in late 2026, subject to clinical and patient feedback. The expectation is not verified general delivery as of November 2, 2026. Exact mass, battery, speed, configuration, control interface and first-release date remain unverified; Indego Personal/Therapy and EksoNR specifications are not inherited.
Specifications
Sources cover the marked fields only. Unmarked values have not been checked in this review; manufacturer figures are not independent test results.